- Abbott Laboratories
- F. Hoffmann-La Roche Ltd
- Chembio Diagnostics, Inc.
- Quidel Corp
- Nectar Lifesciences Ltd (Rapikit)
- Bionime Corp
- Becton, Dickinson & Co.
- PRIMA Lab
- Atlas Medical UK
- OraSure Technologies
- B. Braun Melsungen AG
- Lifescan Inc
- Troge Medical Gmbh
- Nova Biomedical
- Siemens Healthcare
- Cardinal Health, Inc
- EmsiG GmbH Co
- Acon Laboratories Inc.
- Trividia Health, Inc.
- TaiDoc Technology Corporation
Recent developments by key players in the Global At Home Diagnostics Market:
Abbott Laboratories
Holds approximately 20% of the market share in at-home diagnostics and has recently launched more affordable and connected continuous glucose monitoring (CGM) systems, such as Libre Rio and Lingo, with enhanced mobile integration and real-time data transmission for diabetes self-management.
Quidel Corp
Expanded its portfolio by introducing rapid at-home antigen tests, including for influenza, to align with the growing consumer demand for convenient self-testing tools.
Becton, Dickinson & Co. (BD)
In mid-2024, BD partnered with Healthians in India to launch at-home self-collection kits for cervical cancer screening. This initiative enables women to collect HPV samples from home and receive extended genotyping results, significantly improving screening uptake in underserved populations.
In April 2021, to enhance access to HIV self-testing in Low and Middle-Income Countries, Viatris and Atomo Diagnostics committed to working with Unitaid, with an aim to make HIV testing available in 135 countries. The Unitaid expansion programme financed the distribution of up to 1 million HIV self-test kits.
The global at-home diagnostic market is a rapidly growing industry driven by various factors, such as the increasing incidence of chronic illnesses, rising awareness about preventive healthcare, technological advancements, and the growing demand for personalized medicine. The COVID-19 pandemic has influenced the growth of this market as people have become more cautious about visiting hospitals and clinics, leading to a higher demand for at-home diagnostic tests. One of the major factors driving the expansion of the at-home diagnostic market is the increasing prevalence of chronic disorders including diabetes, cancer, cardiovascular diseases, and respiratory diseases. The availability of at-home diagnostic tests allows patients to monitor their health regularly, which can help in early detection of these diseases and prevent further complications. Moreover, there is a growing trend of people taking control of their health and being proactive about preventative care. At-home diagnostic tests provide a convenient and accessible way to monitor one's health without regular visits to healthcare facilities.
Furthermore, the demand for personalized medicine has also driven the growth of the at-home diagnostic market. At-home diagnostic tests can provide a more customized approach to healthcare by allowing patients to monitor their health more closely and tailor their treatment plans accordingly. However, the global at-home diagnostic market faces restraints that could hinder its growth. These restraints include a lack of standardization, regulatory challenges, limited test accuracy, limited availability of advanced tests, and limited reimbursement. Despite these challenges, the market is expected to continue to grow in the forecast period.